Journal of Surgery Concepts & Practice >

2026 , Vol. 31 >Issue 03: 212 - 217

DOI: https://doi.org/10.16139/j.1007-9610.2026.03.06

Experts forum

Application and prospects of circulating tumor DNA in the precision diagnosis and treatment of breast cancer

  • WANG Haoyu ,
  • ZHU Siji ,
  • LI Anqi ,
  • CHEN Xiaosong
Expand
  • a. Department of General Surgery, Comprehensive Breast Health Center; b. Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2026-06-10

  Online published: 2026-08-11

Fold

Abstract

Circulating tumor DNA (ctDNA) represents the liquid biopsy technology with the most advanced clinical translation and the deepest research foundation to date. Leveraging its non-invasive, dynamic, and highly specific advantages, ctDNA has emerged as an important breakthrough direction in the precision diagnosis and treatment of breast cancer. In this article, we systematically reviewed the detection methodologies of ctDNA, with a dedicated focus on its clinical utility and current research status across different stages of breast cancer management. Furthermore, we provided a forward-looking perspective on the future development of ctDNA in guiding the full-course precision management of breast cancer.

Key words： Breast cancer; Circulating tumor DNA(ctDNA); Precision medicine; Prognostic prediction; Efficacy evaluation

Cite this article

WANG Haoyu , ZHU Siji , LI Anqi , CHEN Xiaosong . Application and prospects of circulating tumor DNA in the precision diagnosis and treatment of breast cancer[J]. Journal of Surgery Concepts & Practice, 2026 , 31(03) : 212 -217 . DOI: 10.16139/j.1007-9610.2026.03.06

References

[1] 中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组, 邵志敏, 等. 中国抗癌协会乳腺癌诊治指南与规范(2026年版)[J]. 中国癌症杂志, 2025, 35(12) :1157-1255.
  China Anti-Cancer Association-Committee of Breast Cancer Society (CACA-CBCS), Chinese Medical Association Society of Oncology Breast Oncology Group, Shao Zhimin, et al. China anti-cancer association breast cancer guidelines and standards for the diagnosis and treatment (2026)[J]. China Oncol, 2025, 35(12):1157-1255.
[2] Goldhirsch A, Winer E P, Coates A S, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24(9):2206-2223.
[3] Sparano J A, Gray R J, Makower D F, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2018, 379(2):111-121.
[4] Bedrosian I, Somerfield M R, Achatz M I, et al. Germline testing in patients with breast cancer: ASCO-Society of surgical oncology guideline[J]. J Clin Oncol, 2024, 42(5):584-604.
[5] Wan J C M, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circula-ting tumour DNA[J]. Nat Rev Cancer, 2017, 17(4):223-238.
[6] Ignatiadis M, Sledge G W, Jeffrey S S. Liquid biopsy enters the clinic - implementation issues and future challenges[J]. Nat Rev Clin Oncol, 2021, 18(5):297-312.
[7] Panet F, Papakonstantinou A, Borrell M, et al. Use of ctDNA in early breast cancer: analytical validity and clinical potential[J]. NPJ Breast Cancer, 2024, 10(1):50.
[8] Martínez-Sáez O, Chic N, Pascual T, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer[J]. Breast Cancer Res, 2020, 22(1):45.
[9] Marra A, Kim S H, Pareja F, et al. Tracking response to neoadjuvant systemic therapy through circulating tumor DNA analysis in breast cancer[J]. NPJ Breast Cancer, 2026, 12(1):57.
[10] McDonald B R, Contente-Cuomo T, Sammut S J, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer[J]. Sci Transl Med, 2019, 11(504):eaax7392.
[11] Elliott M J, Howarth K, Main S, et al. Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer[J]. Clin Cancer Res, 2025, 31(8):1520-1532.
[12] Elliott M J, Kim J, Dou A, et al. Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer[J]. ESMO Open, 2025, 10(6):105286.
[13] Santonja A, Cooper W N, Eldridge M D, et al. Comparison of tumor-informed and tumor-na?ve sequencing assays for ctDNA detection in breast cancer[J]. EMBO Mol Med, 2023, 15(6):e16505.
[14] Cunningham N, Coakley M, Cutts R, et al. A comparative analysis between tissue-free ctDNA detection and a multivariant tumour-informed assay in early triple-negative breast cancer[C]. Berlin: ESMO Breast Cancer Congress, 2026.
[15] Angus L, Smid M, Wilting S M, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies[J]. Nat Genet, 2019, 51(10):1450-1458.
[16] Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer[J]. Ann Oncol, 2020, 31(3):377-386.
[17] André F, Ciruelos E M, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1[J]. Ann Oncol, 2021, 32(2):208-217.
[18] Tolaney S M, Toi M, Neven P, et al. Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant[J]. Cancer Res, 2019, 79 (13_Suppl):4458.
[19] Bidard F C, Hardy-Bessard A C, Dalenc F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(11):1367-1377.
[20] Bidard F C, Mayer E L, Park Y H, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer[J]. N Engl J Med, 2025, 393(6):569-580.
[21] Francois C B, Erica L M, Yeon H P, et al. First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): final progression-free survival 2 (PFS2) from the phase Ⅲ SERENA-6 trial[J]. J Clin Oncol 44,LBA1007-LBA1007(2026).
[22] Coombes R C, Page K, Salari R, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence[J]. Clin Cancer Res, 2019, 25(14):4255-4263.
[23] Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer[J]. JAMA Oncol, 2019, 5(10):1473-1478.
[24] Johnston S, Martin M, O'Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer[J]. Ann Oncol, 2026, 37(2):155-165.
[25] Sherene L, Stephen R D, Carlos L A, et al. Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)[J]. J Clin Oncol 42,LBA507-LBA507(2024).
[26] Turner N C, Swift C, Jenkins B, et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer[J]. Ann Oncol, 2023, 34(2):200-211.
[27] Cunningham N, Sardo-Infirri S, Swift C, et al. 1O ctDNA detection rates during surveillance in high-risk HR+/HER2-negative breast cancer from the TRAK-ER study[C]. Berlin: ESMO Breast Cancer Congress, 2026.
[28] Lajos P, Carly B S, Ekaterina K, et al. Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy[J]. J Clin Oncol 43,1010- 1010 (2025).
[29] Medford A J, Scalise C, Dhulekar S, et al. Personalized circulating tumor DNA (ctDNA) testing, intervention, and temporal dynamics in ER+/HER2-early-stage breast cancer (LEADER)[J]. Clin Cancer Res, 2026, 32(4_Suppl):PD5-01.
[30] Magbanua M J M, Brown S L, Ahmed Z, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy[J]. Cancer Cell, 2023, 41(6):1091-1102.e4.
[31] Pérez-García J M, Cortés J, Ruiz-Borrego M, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial[J]. Lancet, 2024, 403(10437):1649-1659.
[32] Wang H, Lu Y, Zhang B, et al. Tumor-informed ctDNA dynamics and efficacy of sequential pyrotinib-pertuzumab neoadjuvant therapy in HER2-positive breast cancer: a randomized, open-label, phase Ⅱ trial[J]. ESMO Open, 2026, 11(Suppl 4):106967.
[33] Valenza C, Saldanha E F, Gong Y, et al. Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Ann Oncol, 2025, 36(7):726-736.
[34] Hunter N B, Parsons H A, Cope L, et al. The pathologic response evaluation and detection in circulating tumor-DNA study: ultrasensitive circulating tumor-DNA assessment of breast cancer minimal residual disease[J]. J Clin Oncol, 2026, 44(14):1283-1295.
Options
Outlines

/

〈 〉